146 related articles for article (PubMed ID: 10573961)
21. Surveillance for antimicrobial resistance among clinical isolates of gram-negative bacteria from intensive care unit patients in China, 1996 to 2002.
Wang H; Chen M;
Diagn Microbiol Infect Dis; 2005 Mar; 51(3):201-8. PubMed ID: 15766607
[TBL] [Abstract][Full Text] [Related]
22. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
23. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.
Walsh TR
Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():2-9. PubMed ID: 16209700
[TBL] [Abstract][Full Text] [Related]
24. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
Xiong Z; Zhu D; Zhang Y; Wang F
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
[TBL] [Abstract][Full Text] [Related]
25. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy.
Bush K
Clin Infect Dis; 2001 Apr; 32(7):1085-9. PubMed ID: 11264037
[TBL] [Abstract][Full Text] [Related]
26. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
Hawkey P; Finch R
Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318
[TBL] [Abstract][Full Text] [Related]
27. In vitro evaluation of a new cefixime-clavulanic acid combination for gram-negative bacteria.
Rawat D; Hasan AS; Capoor MR; Sarma S; Nair D; Deb M; Pillai P; Aggarwal P
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):131-9. PubMed ID: 19323045
[TBL] [Abstract][Full Text] [Related]
28. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
[TBL] [Abstract][Full Text] [Related]
29. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
Jones RN; Sader HS; Fritsche TR
Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
[TBL] [Abstract][Full Text] [Related]
30. [Beta-lactamases in laboratory and their role in resistance Part I.: Evolution of bacterial resistance mediated by beta-lactamases].
Bedenić B
Lijec Vjesn; 2004; 126(11-12):314-24. PubMed ID: 16082890
[TBL] [Abstract][Full Text] [Related]
31. Enteric gram-negative bacilli bloodstream infections: 17 years' experience in a neonatal intensive care unit.
Cordero L; Rau R; Taylor D; Ayers LW
Am J Infect Control; 2004 Jun; 32(4):189-95. PubMed ID: 15175611
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the antimicrobial resistance patterns of gram-negative bacilli isolated from community-private and university-affiliated hospitals from Puerto Rico.
Vázquez GJ; Robledo IE; Arroyo A; Nadal E; Rodríguez R; Bermúdez M; Colón M
P R Health Sci J; 2003 Sep; 22(3):265-71. PubMed ID: 14619453
[TBL] [Abstract][Full Text] [Related]
33. [Beta-lactamases and their role in resistance. PART 2: beta-lactamases in 21st century].
Bedenić B
Lijec Vjesn; 2005; 127(1-2):12-21. PubMed ID: 16145868
[TBL] [Abstract][Full Text] [Related]
34. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
Zarakolu P; Hasçelik G; Unal S
Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
[TBL] [Abstract][Full Text] [Related]
35. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
36. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
37. [Monitoring of bacteria resistance in burn patients].
Zhang M; Xu X; Liao P
Zhonghua Wai Ke Za Zhi; 1999 May; 37(5):278-81. PubMed ID: 11829839
[TBL] [Abstract][Full Text] [Related]
38. beta-Lactam resistance and beta-lactamases in bacteria of animal origin.
Li XZ; Mehrotra M; Ghimire S; Adewoye L
Vet Microbiol; 2007 Apr; 121(3-4):197-214. PubMed ID: 17306475
[TBL] [Abstract][Full Text] [Related]
39. Activity of oral beta-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance.
Doern GV
Otolaryngol Head Neck Surg; 2002 Dec; 127(6 Suppl):S17-23. PubMed ID: 12511856
[TBL] [Abstract][Full Text] [Related]
40. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
